Drug intelligence / Profile preview

irbesartan

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Irbesartan is an angiotensin II receptor blocker (ARB) used primarily to treat high blood pressure (hypertension) and to protect kidney function in people with type 2 diabetes and nephropathy. It works by selectively blocking the AT1 subtype of angiotensin II receptors in tissues such as vascular smooth muscle and the adrenal gland. This blockade prevents angiotensin II from causing vasoconstriction and aldosterone secretion, resulting in relaxation of blood vessels and reduced blood pressure. Irbesartan has a much higher affinity for the AT1 receptor than for the AT2 receptor (over 8500-fold). It is taken orally once daily due to its long duration of action. Developed by Sanofi.

Brand names
AvaproKarveaIfirmacombiKarvezideAvalide
Other names
irbesartanum
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on irbesartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on irbesartan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call